Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 5;172(9):625-626.
doi: 10.7326/M20-1023. Epub 2020 Mar 31.

A Clinical Trial of Isradipine: What Went Wrong?

Baijayanta Maiti  1 , Joel S Perlmutter  1
Affiliations

A Clinical Trial of Isradipine: What Went Wrong?

Baijayanta Maiti et al. Ann Intern Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-1023.

References

    1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–6. - PubMed
    1. The Parkinson Study Group STEADY-PD III Investigators. Isradipine versus placebo in early Parkinson disease. A randomized trial. Ann Intern Med. 2020;172:591–8. doi:10.7326/M19-2534 - DOI - PMC - PubMed
    1. Surmeier DJ, Guzman JN, Sanchez J, et al. Physiological phenotype and vulnerability in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a009290. doi:10.1101/cshperspect.a009290 - DOI - PMC - PubMed
    1. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis. 2011;43:364–71. doi:10.1016/j.nbd.2011.04.007 - DOI - PMC - PubMed
    1. Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67:600–6. doi:10.1002/ana.21937 - DOI - PMC - PubMed

MeSH terms